On our first episode of ‘Talk Radioisotopes: Going Nuclear on Cancer,’ host Scott Larrivee is joined by co-host Dr. Sarah Scouten and guest Jeff Jones of Oppenheimer & Company.
The discussion covers the latest trends in the radiopharmaceutical and radiotherapeutics markets, including the rise of targeted radiotherapies, the involvement of large pharmaceutical companies, and key developments in isotope supply chains.
Jeff provides insights from Oppenheimer’s recent summit on radiotherapy, covering emerging technologies, new isotopes, and the regulatory and logistical challenges ahead. Sarah discusses the broader implications for the oncology field and the importance of clinician and infrastructure readiness.
The episode concludes with a look ahead to 2025, discussing potential advancements, technological innovations, and how the political landscape might impact the future of cancer treatments.
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
The following is a copy of a press release issued by Cellectar BiosciencesPartnership Provides Long-Term Supply of...
